<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Polypharma: Generics Developer</title>
	<atom:link href="https://polypharma.de/en/feed/" rel="self" type="application/rss+xml" />
	<link>https://polypharma.de</link>
	<description>Full-service in the production of generics and delivery of raw materials in Africa and the Middle East</description>
	<lastBuildDate>Wed, 29 Sep 2021 10:49:56 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://polypharma.de/wp-content/uploads/2020/07/cropped-Polypharma-Technologies-and-Sciences-Hamburg-150x150.png</url>
	<title>Polypharma: Generics Developer</title>
	<link>https://polypharma.de</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Polypharma project planning for MENA pharma facilities</title>
		<link>https://polypharma.de/en/2021/08/polypharma-project-planning-for-mena-pharma-facilities/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 04 Aug 2021 12:00:57 +0000</pubDate>
				<category><![CDATA[Factory construction]]></category>
		<category><![CDATA[Manufacturing Process]]></category>
		<category><![CDATA[Pharmaceutical Raw Materials / Laboratory Equipment]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[construction]]></category>
		<category><![CDATA[Consultant]]></category>
		<category><![CDATA[Developer]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Drug Master File]]></category>
		<category><![CDATA[factory planning]]></category>
		<category><![CDATA[generic manufacture]]></category>
		<category><![CDATA[generic pharma]]></category>
		<category><![CDATA[market opportunity analysis]]></category>
		<category><![CDATA[MENA]]></category>
		<category><![CDATA[MENA market]]></category>
		<category><![CDATA[MENA pharma facilities]]></category>
		<category><![CDATA[Middle East]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[project feasibility]]></category>
		<category><![CDATA[project planning]]></category>
		<category><![CDATA[project schedule]]></category>
		<category><![CDATA[project timeline]]></category>
		<category><![CDATA[raw material]]></category>
		<category><![CDATA[Sciences]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[supply]]></category>
		<category><![CDATA[tech transfer]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[technology transfer]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=9079</guid>

					<description><![CDATA[Core competencies of Polypharma include project planning, feasibility studies, plant construction, technology transfer, pharmaceutical development, and materials sourcing and supply. Its full service offerings can include all these elements to provide a total solution for pharmaceutical developers and producers that can also include processing registrations, with on-site services that include all necessary API-manufacturer documentation, such as [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Polypharma marks World Cholesterol Day</title>
		<link>https://polypharma.de/en/2021/06/polypharma-marks-world-cholesterol-day/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 21 Jun 2021 12:37:48 +0000</pubDate>
				<category><![CDATA[Fairs / Events]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[angiology]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cardiology]]></category>
		<category><![CDATA[cholestérol]]></category>
		<category><![CDATA[Consultant]]></category>
		<category><![CDATA[Developer]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[generic manufacture]]></category>
		<category><![CDATA[MENA]]></category>
		<category><![CDATA[Middle East]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[raw material]]></category>
		<category><![CDATA[Sciences]]></category>
		<category><![CDATA[supply]]></category>
		<category><![CDATA[Technologies]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=8695</guid>

					<description><![CDATA[Hamburg, Germany: Specialist pharmaceutical consultant and supplier Polypharma Technologies &#38; Sciences GmbH (Polypharma) has been marking international Cholesterol Day. The substance cholesterol is involved in metabolic processes in the body, primarily in the metabolization of fat. The body covers its need for cholesterol by producing it in the liver and taking it from food. If [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Polypharma celebrates 30th Anniversary</title>
		<link>https://polypharma.de/en/2021/06/polypharma-celebrates-30th-anniversary/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 18 Jun 2021 08:27:42 +0000</pubDate>
				<category><![CDATA[Counterfeit Medicines]]></category>
		<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[Factory construction]]></category>
		<category><![CDATA[Fairs / Events]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Manufacturing Process]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Pharmaceutical Raw Materials / Laboratory Equipment]]></category>
		<category><![CDATA[Registration Process]]></category>
		<category><![CDATA[30 years]]></category>
		<category><![CDATA[30th anniversary]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[construction]]></category>
		<category><![CDATA[Consultant]]></category>
		<category><![CDATA[Developer]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Drug Master File]]></category>
		<category><![CDATA[food supplements]]></category>
		<category><![CDATA[generic manufacture]]></category>
		<category><![CDATA[MENA]]></category>
		<category><![CDATA[Middle East]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[raw material]]></category>
		<category><![CDATA[Sciences]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[supply]]></category>
		<category><![CDATA[Technologies]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=8650</guid>

					<description><![CDATA[Single partner Polypharma offers a unique blend of services and skills that make it possible for it to act as a single partner accompanying local companies all the way from selection of target product through to actual receipt of raw materials for production. “Over the years we have developed more than 200 approved drug dossiers [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Sodium hyaluronate 0.3% Serum</title>
		<link>https://polypharma.de/en/2021/01/sodium-hyaluronate-0-3-serum-2/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 29 Jan 2021 15:04:49 +0000</pubDate>
				<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[hyaluronic acid]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[sodium hyaluronate]]></category>
		<category><![CDATA[tech transfer]]></category>
		<category><![CDATA[technical transfer]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7931</guid>

					<description><![CDATA[Polypharma has developed a Sodium hyaluronate 0.3% serum. Sodium hyaluronate, as hyaluronic acid, is a natural component of the skin and is used to smooth and tighten the skin, as well as to moisturise it.]]></description>
		
		
		
			</item>
		<item>
		<title>Dossiers Betamethasone dipropionate 0.05% Lotion and Creme</title>
		<link>https://polypharma.de/en/2020/12/dossiers-betamethasone-dipropionate-lotion-and-creme-2/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 15 Dec 2020 15:02:13 +0000</pubDate>
				<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[betamethasone]]></category>
		<category><![CDATA[betamethasone dipropionate]]></category>
		<category><![CDATA[dossiers]]></category>
		<category><![CDATA[Know How]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma Technologies & Sciences GmbH]]></category>
		<category><![CDATA[tech transfer]]></category>
		<category><![CDATA[technical dossiers]]></category>
		<category><![CDATA[technical transfer]]></category>
		<category><![CDATA[technology transfer]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7925</guid>

					<description><![CDATA[The technical dossiers for Betamethasone dipropionate 0.05% lotion and Betamethasone dipropionate cream have been completed by Polypharma. This glucocorticoid is used to treat dermatitis, eczema and psoriasis.]]></description>
		
		
		
			</item>
		<item>
		<title>Website relaunch</title>
		<link>https://polypharma.de/en/2020/12/website-relaunch/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Sat, 05 Dec 2020 18:20:39 +0000</pubDate>
				<category><![CDATA[Others]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[Polypharma Technologies & Sciences GmbH]]></category>
		<category><![CDATA[website relaunch]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7186</guid>

					<description><![CDATA[Our new website is online. Chlick for more: www.polypharma.de/en]]></description>
		
		
		
			</item>
		<item>
		<title>API representation</title>
		<link>https://polypharma.de/en/2020/12/api-representation/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 01 Dec 2020 14:30:14 +0000</pubDate>
				<category><![CDATA[Pharmaceutical Raw Materials / Laboratory Equipment]]></category>
		<category><![CDATA[API representation]]></category>
		<category><![CDATA[API representative]]></category>
		<category><![CDATA[Bupivacain]]></category>
		<category><![CDATA[Donepezil]]></category>
		<category><![CDATA[Gliclazide]]></category>
		<category><![CDATA[Glimepiride]]></category>
		<category><![CDATA[Mepivacain]]></category>
		<category><![CDATA[Olanzapine]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[Polypharma Technologies & Sciences GmbH]]></category>
		<category><![CDATA[Ropivacain]]></category>
		<category><![CDATA[Zolpidem]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7698</guid>

					<description><![CDATA[Polypharma is now the representative of a Tunisian API manufacturer for: Donepezil Glimepiride (micronised) Bupivacaine Mepivacaine Ropivacaine Gliclazide Zolpidem Olanzapine If you are interested, send us a message by using our contact form or get in touch with us at: info[at]polypharma.de]]></description>
		
		
		
			</item>
		<item>
		<title>Terbinafine hydrochloride 1% solution</title>
		<link>https://polypharma.de/en/2020/11/terbinafine-hydrochloride-1-solution/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 16 Nov 2020 14:59:00 +0000</pubDate>
				<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[antifungal]]></category>
		<category><![CDATA[antifungal agent]]></category>
		<category><![CDATA[dossier]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[Polypharma Technologies & Sciences GmbH]]></category>
		<category><![CDATA[technical dossiers]]></category>
		<category><![CDATA[Terbinafine]]></category>
		<category><![CDATA[Terbinafine hydrochloride]]></category>
		<category><![CDATA[Terbinafine hydrochloride spray]]></category>
		<category><![CDATA[Terbinafine Spray]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7919</guid>

					<description><![CDATA[Polypharma has developed a Terbinafine hydrochloride 1% spray solution for topical application. Terbinafine is an antifungal agent and the most commonly used treatment for skin and foot fungal infections.]]></description>
		
		
		
			</item>
		<item>
		<title>Why Polypharma cannot recommend its partners to package purchased bulk medicines</title>
		<link>https://polypharma.de/en/2020/11/buying-bulk-medicines-not-recommended/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 16 Nov 2020 08:38:31 +0000</pubDate>
				<category><![CDATA[Manufacturing Process]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=9371</guid>

					<description><![CDATA[Many new customers find it interesting to pack already manufactured goods as a first step before producing their own medicines. Here are the reasons why Polypharma cannot recommend buying bulk medicines: From a pharmaceutical point of view, production and packaging in a GMP-compliant production line is the highest priority for the quality of the pharmaceuticals [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>CPhI Worldwide 2020 in Milan</title>
		<link>https://polypharma.de/en/2020/10/cphi-worldwide-2020-in-milan-en/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 13 Oct 2020 09:26:02 +0000</pubDate>
				<category><![CDATA[Fairs / Events]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[CPhI]]></category>
		<category><![CDATA[CPhI worldwide]]></category>
		<category><![CDATA[dossier]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[pharmaceutical excipients]]></category>
		<category><![CDATA[pharmaceutical raw material]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[Polypharma Technologies & Sciences GmbH]]></category>
		<category><![CDATA[technical dossiers]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6459</guid>

					<description><![CDATA[]]></description>
		
		
		
			</item>
		<item>
		<title>Diclofenac diethylamine 1% gel</title>
		<link>https://polypharma.de/en/2020/09/diclofenac-diethylamine-1-gel-2/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 15 Sep 2020 14:55:39 +0000</pubDate>
				<category><![CDATA[Development / Dossiers]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7913</guid>

					<description><![CDATA[Polypharma has completed the preparation of a technical dossier for a gel based on 1% diethylamine diclofenac. Diclofenac diethylamine has an analgesic, anti-inflammatory and refreshing effect. It can be used to treat sports injuries, sunburn and arthritis.]]></description>
		
		
		
			</item>
		<item>
		<title>Calcipotriol ointment developed</title>
		<link>https://polypharma.de/en/2020/09/calcipotriol-ointment-developed/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Thu, 03 Sep 2020 11:42:12 +0000</pubDate>
				<category><![CDATA[Development / Dossiers]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6621</guid>

					<description><![CDATA[With this ointment Polypharma is also expanding its portfolio of dermatology products. A product extremely effective for the external treatment of psoriasis. This D3 derivative disrupts the growth and proliferation of keratinocytes and improves the disturbed cell separation.]]></description>
		
		
		
			</item>
		<item>
		<title>High concentration drugs now injectable</title>
		<link>https://polypharma.de/en/2020/08/high-concentration-drugs-now-injectable/</link>
		
		<dc:creator><![CDATA[Elidona Dalipaj]]></dc:creator>
		<pubDate>Thu, 27 Aug 2020 11:28:21 +0000</pubDate>
				<category><![CDATA[Innovation]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7765</guid>

					<description><![CDATA[The researchers designed a system that made it possible to inject highly concentrated drug formulations subcutaneously while reducing the required injection force, which exceeded what is possible with manual subcutaneous injection using a conventional syringe.]]></description>
		
		
		
			</item>
		<item>
		<title>The impact of indoor air humidity content on Covid-19</title>
		<link>https://polypharma.de/en/2020/08/the-impact-of-indoor-air-humidity-content-on-covid-19/</link>
		
		<dc:creator><![CDATA[Elidona Dalipaj]]></dc:creator>
		<pubDate>Tue, 25 Aug 2020 11:25:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7759</guid>

					<description><![CDATA[Humidity levels of at least 40% in public buildings and public transport would not only reduce the impact of COVID-19, but also that of other viral diseases such as seasonal influenza. Authorities should incorporate the humidity factor into future guidelines for interiors.]]></description>
		
		
		
			</item>
		<item>
		<title>Formulations that enhance bioavailability</title>
		<link>https://polypharma.de/en/2020/08/formulations-that-enhance-bioavailability/</link>
		
		<dc:creator><![CDATA[Elidona Dalipaj]]></dc:creator>
		<pubDate>Tue, 25 Aug 2020 11:23:01 +0000</pubDate>
				<category><![CDATA[Manufacturing Process]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=7753</guid>

					<description><![CDATA[It is useful to combine in vitro testing and in silico modelling to predict and understand the in vivo performance of formulations that improve bioavailability, resulting in a successful in vivo test for belinostat. The key factor for in vivo performance was determined to be dissolution in the stomach prior to transit in the proximal [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
